Lilly Adds PhIII Intranasal Glucagon To Diabetes Arsenal
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co has acquired the worldwide rights to Locemia Solutions' Phase III intranasal glucagon product for the treatment of severe hypoglycemia – which it hopes will be the first needle-free option to gain approval for this indication.
You may also be interested in...
Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon
The latest drug development news and highlights from our US FDA Performance Tracker.
Phase III Data Put Zealand's Dasiglucagon On Track, But Behind Others, For Hypoglycemia Rescue
Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.